08:00 , Mar 5, 2012 |  BioCentury  |  Product Development

Kalydescopic vision

FDA's approval of Kalydeco ivacaftor for a small subset of cystic fibrosis patients - three months ahead of the PDUFA goal and five and a half years after Vertex Pharmaceuticals Inc. started the first clinical...
08:00 , Feb 21, 2011 |  BioCentury  |  Strategy

Sweet Spot revisited

Another biotechnology pioneer is being swept away by an innovation-starved big pharmaceutical company, the latest reflection of the bleak outlook of a biopharma industry blanketed by R&D failures, hostile regulators, unwilling payers and the flight...
08:00 , Dec 19, 2005 |  BioCentury  |  Tools & Techniques

Selecting for pain

Neuropathic pain is difficult to both diagnose and treat, as current first-line therapies such as anticonvulsants and antidepressants mostly have been discovered serendipitously, provide only partial relief and are limited by side effects. Consequently, there...
07:00 , Sep 13, 2004 |  BC Week In Review  |  Company News

Santhera Pharmaceuticals AG board of directors update

Santhera Pharmaceuticals AG , Liestal, Switzerland   Business: Musculoskeletal, Metabolic, Functional genomics   Appointed: Mark Clement, CEO of Merlin BioSciences; Ruedi Gygax, managing director of Novartis Venture Fund; Michael Lytton, general partner at Oxford Bioscience...
07:00 , Sep 6, 2004 |  BioCentury  |  Strategy

Asset accumulation

A few months ago, BioCentury spilled a lot of ink to deconstruct the NRDO model of no-research, development only companies being formed to scavenge for products or technologies that can be commercialized quickly and offer...
07:00 , Jun 14, 2004 |  BioCentury  |  Tools & Techniques

Correcting CF with small molecules

So little has happened for cystic fibrosis patients over the past decade that it was notable last week when Vertex Pharmaceuticals Inc. said it has identified a group of small molecules that have shown the...
08:00 , Dec 9, 2003 |  BC Extra  |  Company News

Xencor names Stylli CEO

Monoclonal antibody company Xencor hired Harry Stylli as president, CEO and a director. He replaces Bassil Dahiyat, who becomes CSO. Stylli most recently was president and CEO of CovX Pharmaceuticals. He also co-founded Aurora Biosciences,...
08:00 , Dec 8, 2003 |  BC Week In Review  |  Company News

Vertex, Telegraph Hill Partners deal

VRTX will exit the tools and service business through the sale to Aurora Discovery of the liquid- and cell-dispensing instrument technologies of VRTX's Aurora Instruments subsidiary. Aurora Discovery is a new company formed by Telegraph...
08:00 , Dec 4, 2003 |  BC Extra  |  Company News

Vertex selling assets of Aurora Instruments

VRTX will exit the tools and service business through the sale of the liquid and cell-dispensing instrument technologies of its Aurora Instruments subsidiary to Aurora Discovery. Aurora Discovery is a new company formed by Telegraph...
08:00 , Nov 24, 2003 |  BioCentury  |  Strategy

Platform acquisitions

Platform acquisitions Acquirer Date Acquired Value Assets Value chain segment DuPont Pharma (now part of Bristol-Myers) 1999 CombiChem $95 Combinatorial chemistry Lead generation/optimization Eli Lilly (A) 2003 Applied Molecular Evolution $400 Directed molecular evolution technology...